https://www.mdlinx.com/internal-medicine/medical-news-article/2017/06/16/cholesterol-ldl-hydroxymethylglutaryl-coa-reductase-inhibitors/7213624/?news_id=387&newsdt=062417&subspec_id=4&utm_source=WeeklyNL&utm_medium=newsletter&utm_content=Weeks-Best-Article&utm_campaign=article-section&category=latest-weekly
Journal of Clinical Lipidology
Awad K, et al. – This study
explored the impacts of morning versus evening statin administration on
lipid profile. As per findings, evening–dose of short–acting statins
markedly reduced low density lipoprotein cholesterol (LDL-C) and total
cholesterol (TC) levels than morning–dose, whereas, long–acting statins
exerted slight but significant impact on LDL-C and displayed equivalent
efficacy for both regimens. Overall, it was recommended that long–acting
statins should be given at a time that will best aid compliance,
whereas, short–acting statins should be given in the evening.
Methods
- Researchers searched PubMed, SCOPUS, Web of Science and Embase databases (from inception up to July 24th, 2016) to identify the relevant studies.
- Using a fixed-effect model, they pooled mean differences (MDs) between the change scores in lipid parameters.
Results
- For this analysis, eleven articles with 1034 participants were found to be eligible.
- Researchers found that the pooled analysis comparing impacts of morning versus evening administration of statins on plasma total cholesterol (TC) (p=0.10), high density lipoprotein cholesterol (HDL-C) (p=0.90) and triglycerides (TG) (p=0.45) was not statistically significant.
- They also noted that low density lipoprotein cholesterol (LDL-C) lowering was statistically greater in the evening-dose group (MD: 3.24 mg/dl, 95%CI: 1.23, 5.25, p=0.002).
- It was demonstrated in subgroup analysis according to statin half-lives that evening-dose of statins was significantly superior to morning-dose for lowering LDL-C in case of both short and long half-life statins (MD: 9.68 mg/dl, 95%CI: 3.32, 16.03, p=0.003, and 2.53 mg/dl, 95%CI: 0.41, 4.64, p=0.02, respectively), and also for TC reduction in case of short half-life statins only (p=0.0005).
No comments:
Post a Comment